Council Member Sandra Ung and leaders from the Charles B. Wang Community Health Center will host a free hepatitis B screening ...

We are writing to respond to comments from Joshua W Miller and colleagues1 regarding our 2024 report of the Lancet standing Commission on dementia prevention, intervention, and care.2 Miller and ...

Researchers say if their results are confirmed through further study they are optimistic the approach could be used to treat chronic infections for the first time.

Dynavax reports record HEPLISAV-B revenue, 26% growth in 2024, and strong 2025 guidance. Insights on shingles vaccine progress & market expansion.

In their effort to answer a decades-old biological question about how the hepatitis B virus (HBV) is able to establish infection of liver cells, research led by Memorial Sloan Kettering Cancer Center ...

In their effort to answer a decades-old biological question about how the hepatitis B virus (HBV) is able to establish infection of liver cells, researchers have identified a vulnerability that opens ...

Nucleoside analogs are transformative in cancer and antiviral therapies, offering new avenues for treatment despite ...

Precision BioSciences reports early PBGENE-HBV trial data showing safety and antiviral activity in chronic Hepatitis B patients, with more results expected in 2025.

Dynavax Technologies (NASDAQ:DVAX – Get Free Report) was downgraded by equities researchers at The Goldman Sachs Group from a “neutral” rating to a “sell” rating in a research report issued on Tuesday ...

This guide includes an overview of practices for the prevention and management of sexually transmitted and blood-borne infections (STBBI) by healthcare professionals practicing in public health or ...

Gilead Sciences reported strong fourth-quarter earnings with significant growth in its HIV and oncology segments.

Goldman Sachs downgraded Dynavax to Sell, citing increased competition in the shingles vaccine market and uncertainty over hepatitis B revaccination demand.